Dickinson Andrew D

Dickinson Andrew D, Chief Financial Officer of Gilead Sciences (GILD), has been a consistent seller of company stock over the past year, with Form 4 filings showing no open-market purchases during the period. The most recent 12 transactions, spanning from August 2025 through July 2026, are all sales or automatic dispositions, with the CFO executing a regular monthly sale of roughly $300,000 to $460,000 on the 15th of each month. These recurring open-market sales total approximately $3.7 million in the most recent quarter alone, with the largest single transaction being a $3.55 million disposition on February 3, 2026, which was paired with a vesting event. The pattern is heavily skewed toward selling, with total sell value across all 60 filings reaching $35.9 million against zero buy value. The monthly sales are punctuated by equity compensation events—grants, option exercises, and tax-withholding dispositions—that are mechanical in nature. For instance, on March 10, 2026, Dickinson received two awards (coded "A") and exercised options (coded "M") at zero value, followed by a $467,518 tax-withholding sale (coded "F") the same day. This structure suggests the regular sales are the only discretionary transactions, and they have been remarkably consistent: from $283,925 in September 2025 to $389,776 in July 2026, with no gaps in the monthly cadence. The direction is unambiguous—a sustained, systematic reduction of GILD holdings by the CFO, with no corresponding accumulation. The absence of any "P" (purchase) codes in the entire filing history, combined with the regularity of the "S" transactions, indicates a deliberate strategy of monetizing equity compensation rather than a reaction to short-term price movements. The total value of sales over the trailing twelve months, approximately $4.5 million from the monthly transactions alone, represents a meaningful portion of the CFO's disclosed holdings, though the exact remaining stake is not specified in these filings.